Nifrtimox for Refractory/Relapsed Neuroblastoma & Medulloblastoma

A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma and Relapsed Medulloblastoma

November 22, 2017

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Leffin, Melissa; Spinelli, Jennifer

  • IRB No: 08.051.07

    Protocol Abbrev: V0706

    Principal Investigator: Don E. Eslin, MD

    Phase: Drug: Phase II

    Age Group: Pediatric

    Secondary Protocol No: V0706

    Treatment: Drug: Nifurtimox Drug: Cyclophosphamide Drug: Topotecan

    Therapies Involved: Chemotherapy ID: NCT00601003

  • Objective

    The purpose of this study is to determine whether nifurtimox in combination with chemotherapy are effective in the treatment of neuroblastoma and medulloblastoma.

  • Key Eligibility

    Ages Eligible for Study: up to 21 Years; Genders Eligible for Study: Both; Accepts Healthy Volunteers: No